Company Description
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.
The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome.
The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM.
The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Oct 23, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 106 |
| CEO | Adrian H. Gottschalk |
Contact Details
Address: 99 Coolidge Avenue, Suite 500 Watertown, Massachusetts 02472 United States | |
| Phone | 617 586 3100 |
| Website | foghorntx.com |
Stock Details
| Ticker Symbol | FHTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001822462 |
| CUSIP Number | 344174107 |
| ISIN Number | US3441741077 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Karin Hellsvik | Chief of Staff to the Chief Executive Officer, Vice President, Head of Corporate Affairs, Investor Relations and Operations |
| Adrian H. B. Gottschalk | President, Chief Executive Officer and Director |
| Dr. Steven F. Bellon Ph.D. | Chief Scientific Officer |
| Dr. Alfonso Quintas Cardama M.D. | Chief Medical Officer |
| Dr. Gerald R. Crabtree M.d. | Founder and Member of Scientific Advisory Board |
| Ryan D. Maynard | Chief Financial Officer |
| Michael J. LaCascia J.D. | Chief Legal Officer |
| Saurabh Sewak Ph.D. | Vice President of Corporate Development |
| Carlos Costa | Chief People Officer |
| Dr. Anna Rivkin Ph.D. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 14, 2026 | SCHEDULE 13G/A | Filing |
| May 7, 2026 | 10-Q | Quarterly Report |
| May 7, 2026 | 8-K | Current Report |
| May 6, 2026 | SCHEDULE 13G/A | Filing |
| Apr 30, 2026 | ARS | Filing |
| Apr 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 21, 2026 | 8-K | Current Report |